● Received a $10 million milestone payment in the third quarter from partner, AbbVie Inc., for achieving a major milestone in the second quarter in accordance with the strategic collaboration agreement related to the clinical-phase dermal filler product candidate Exhibit 99.1 CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023 ● Company is preparing to launch large-animal study with a commercial size breast implant by year-end ● Cash and cash equivalents totaled $29 million as of Se ...

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q2 2023 Earnings Conference Call August 24, 2023 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Ben Haynor - Alliance Global Partners Operator Welcome to the CollPlant Biotechnologies Investor Conference Call to discuss Financial Results for the Second Quarter of 202 ...

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q1 2023 Earnings Conference Call May 24, 2023 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Conference Call Participants Ben Haynor - Alliance Global Partners Swayampakula Ramakanth - H.C. Wainwright Operator Welcome to the CollPlant Biotechnologies Investor Conference Call to discuss Financial Results for the First Quarter of 2023 and Corporate Updates. I'd now like to turn the call over to you ...

Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and it ...

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q4 2022 Earnings Conference Call March 29, 2023 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - Chief Executive Officer Eran Rotem - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Swayampakula Ramakanth - H.C. Wainwright Operator Welcome to the CollPlant Biotechnologies investor conference call to discuss financial results for the full-year 2022 and corporate updates. A question-and-answer ...

● attract and retain skilled personnel; ● create additional infrastructure to support our operations as a public company; and ● experience any delays or encounter issues with any of the above. The net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. In any particular quarter or quarters, our operating results could be below the expectations of secu ...

Exhibit 99.1 Collplant Biotechnologies Announces Full-Year Financial Results For 2022 and Provides Corporate Update ● Continued advancement of strategic collaboration with AbbVie to develop dermal and soft tissue filler products using CollPlant's recombinant human (rh)Collagen ● Additional large-animal study planned in H2 2023 to further 3D bioprinted regenerative breast implant program ● Conference call to be held on March 29, 2023 at 10:00 am U.S. ET; Dial-in information herein Rehovot, Israel, March 29, ...

Exhibit 99.1 CollPlant Biotechnologies Provides Business Updates and Third Quarter 2022 Financial Results ● Partnership with AbbVie to co-develop rhCollagen-based dermal and soft tissue fillers continues to advance according to plan ● Co-developing 3D bioprinted human intestine model ("Gut-on-a-Chip") for drug discovery and personalized treatment of ulcerative colitis with Tel-Aviv University and SHEBA Hospital ● 3D bioprinted regenerative breast implant program on track for Q1 2023 readout of large animal ...

Exhibit 99.2 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2022 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2022 TABLE OF CONTENTS | --- | --- | |-----------------------------------------------------------------------------------|----------------| | CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: | Page | | Condensed Consolidated Balance Sheets | F-2 - F-3 | | Condensed Consolidated Statements of C ...

Exhibit 99.1 CollPlant Biotechnologies Provides Business Updates and Fiscal Year 2021 Financial Results ● Record revenues in 2021 of $15.6 million versus $6.1 million in 2020 ● Continued progress of strategic agreement with AbbVie to develop dermal and soft tissue filler products using CollPlant's rhCollagen ● Company to advance 3D bioprinted regenerative breast implant program with launch of large animal study expected in Q2 ● Strong balance sheet with $43.3 million cash position, as of December 31, 2021 R ...